Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Clin Lung Cancer

Retrieve available abstracts of 277 articles:
HTML format



Single Articles


    December 2022
  1. NESTERYUK V, Hamdani O, Gong R, Almog N, et al
    A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement.
    Clin Lung Cancer. 2022;23:e550-e555.
    PubMed     Abstract available


  2. BANKS KC, Ossowski S, Hung YY, Hsu DS, et al
    Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System.
    Clin Lung Cancer. 2022;23:694-701.
    PubMed     Abstract available


  3. AHN MJ, Mendoza MJL, Pavlakis N, Kato T, et al
    Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
    Clin Lung Cancer. 2022;23:670-685.
    PubMed     Abstract available


  4. KALAND DA, Dores GM, Nayernama A, Camilli S, et al
    U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome.
    Clin Lung Cancer. 2022;23:e556-e562.
    PubMed    


  5. LEAL JL, John T
    Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.
    Clin Lung Cancer. 2022;23:643-658.
    PubMed     Abstract available


  6. ITCHINS M, Ainsworth H, Alexander M, Dean S, et al
    A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.
    Clin Lung Cancer. 2022;23:702-708.
    PubMed     Abstract available


    November 2022
  7. PATEL KG, Corbett RL, Karanjawala ZE, Kelly KA, et al
    A Case of Osimertinib-Induced Eosinophilic Pneumonia.
    Clin Lung Cancer. 2022;23:639-642.
    PubMed    


  8. MACK SJ, Till BM, Huang C, Yang CJ, et al
    Characteristics of High-Volume Lung Segmentectomy Hospitals: A Propensity Score-Matched Analysis.
    Clin Lung Cancer. 2022;23:600-607.
    PubMed     Abstract available


  9. ACKER F, Aguinarte L, Althoff F, Heinzen S, et al
    Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After S
    Clin Lung Cancer. 2022;23:e473-e477.
    PubMed     Abstract available


  10. GIRARD N, Minchom A, Ou SI, Gadgeel SM, et al
    Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2022;23:571-577.
    PubMed     Abstract available


  11. SORSCHER S
    Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline Variants.
    Clin Lung Cancer. 2022;23:e405-e407.
    PubMed     Abstract available


  12. WOO W, Cha YJ, Kim BJ, Moon DH, et al
    Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
    Clin Lung Cancer. 2022;23:e435-e442.
    PubMed     Abstract available


  13. LIU J, Govindarajan A, Williams TM, Kim J, et al
    An Updated Review on Radiation Treatment Management in Thymus Cancers.
    Clin Lung Cancer. 2022;23:561-570.
    PubMed     Abstract available


  14. RUSS DH, Barta JA, Evans NR, Stapp RT, et al
    Volume Doubling Time of Pulmonary Carcinoid Tumors Measured by Computed Tomography.
    Clin Lung Cancer. 2022;23:e453-e459.
    PubMed     Abstract available


  15. HSU R, Herrmann A, Gaur K, Xia B, et al
    Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.
    Clin Lung Cancer. 2022;23:e443-e452.
    PubMed     Abstract available


    October 2022
  16. YANG Y, Zhang Y, Zhao D, Li X, et al
    A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer.
    Clin Lung Cancer. 2022 Oct 14. pii: S1525-7304(22)00211.
    PubMed    


  17. LIN HM, Wu Y, Yin Y, Niu H, et al
    Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2022 Oct 13. pii: S1525-7304(22)00213.
    PubMed     Abstract available


  18. KI MS, Kim SY, Kim EY, Jung JY, et al
    Clinical Outcomes and Prognosis of Patients With Interstitial Lung Disease Undergoing Lung Cancer Surgery: A Propensity Score Matching Study.
    Clin Lung Cancer. 2022 Oct 13. pii: S1525-7304(22)00210.
    PubMed     Abstract available


    September 2022
  19. LI A, Chen HJ, Yang JJ
    Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Tri
    Clin Lung Cancer. 2022 Sep 30. pii: S1525-7304(22)00205.
    PubMed     Abstract available


  20. KUANG Y, Singh R, Nevo A, Deitz AC, et al
    Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.
    Clin Lung Cancer. 2022 Sep 26. pii: S1525-7304(22)00204.
    PubMed     Abstract available


  21. PEVNER JL, Tanvetyanon T
    Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis.
    Clin Lung Cancer. 2022 Sep 25. pii: S1525-7304(22)00206.
    PubMed    


  22. SCHMID S, Cheng S, Chotai S, Garcia M, et al
    Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00209.
    PubMed     Abstract available


  23. GONUGUNTA AS, Von Itzstein MS, Hsiehchen D, Le T, et al
    Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00208.
    PubMed     Abstract available


  24. GUISIER F, Descourt R, Babey H, Huchot E, et al
    Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 >/=50% (GFPC 01-20 Study).
    Clin Lung Cancer. 2022 Sep 17. pii: S1525-7304(22)00203.
    PubMed    


  25. SANTOS ES, Rodriguez E
    Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
    Clin Lung Cancer. 2022;23:457-466.
    PubMed     Abstract available


  26. WU Y, Yin Y, Crossland V, Vincent S, et al
    Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Clin Lung Cancer. 2022;23:487-497.
    PubMed     Abstract available


  27. SHIMODA Y, Shibaki R, Yoshida T, Murakami S, et al
    Concurrent High PD-L1 Expression and CD8(+) Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
    Clin Lung Cancer. 2022;23:477-486.
    PubMed     Abstract available


  28. SPROAT MR, Hofherr ML, Devarakonda S
    Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.
    Clin Lung Cancer. 2022;23:e339-e341.
    PubMed    


    August 2022
  29. OWEN T, Fung AS
    Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report.
    Clin Lung Cancer. 2022 Aug 29. pii: S1525-7304(22)00198.
    PubMed    


  30. MORDANT P MD, PHD, Brosseau S, Milleron B, Santelmo N, et al
    Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
    Clin Lung Cancer. 2022 Aug 29. pii: S1525-7304(22)00197.
    PubMed     Abstract available


  31. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.
    Clin Lung Cancer. 2022 Aug 22. pii: S1525-7304(22)00192.
    PubMed     Abstract available


  32. WANG P, Matton L, Kebir F, Kerrou K, et al
    Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case Report.
    Clin Lung Cancer. 2022 Aug 20. pii: S1525-7304(22)00191.
    PubMed    


  33. YU L, Xu J, Qiao R, Han B, et al
    Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection.
    Clin Lung Cancer. 2022 Aug 15. pii: S1525-7304(22)00189.
    PubMed     Abstract available


  34. PENG L, Du B, Cui Y, Luan Q, et al
    (18)F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer.
    Clin Lung Cancer. 2022 Aug 13. pii: S1525-7304(22)00164.
    PubMed     Abstract available


  35. YU NY, DeWees TA, Voss MM, Breen WG, et al
    Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Aug 10. pii: S1525-7304(22)00170.
    PubMed     Abstract available


  36. GUO M, VanderWalde AM, Yu X, Vidal GA, et al
    Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Clin Lung Cancer. 2022 Aug 8. pii: S1525-7304(22)00166.
    PubMed     Abstract available


  37. GUO MZ, Murray JC, Ghanem P, Voong KR, et al
    Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Aug 8. pii: S1525-7304(22)00173.
    PubMed     Abstract available


  38. ALNIMER Y, Ali MKM
    Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00174.
    PubMed     Abstract available


  39. KIM KH, Yoon S, Ahn HK, Lee SY, et al
    A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00169.
    PubMed     Abstract available


  40. MALLER B, Salvatori S, Tanvetyanon T
    Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis.
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00171.
    PubMed     Abstract available


  41. BANG TJ, Hu J, Patil T, Baron AE, et al
    The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX).
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00172.
    PubMed     Abstract available


    July 2022
  42. HUANG CY, Mack S, Grenda TR, Barta JA, et al
    Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung Cancer.
    Clin Lung Cancer. 2022 Jul 29. pii: S1525-7304(22)00162.
    PubMed     Abstract available


  43. MAZZASCHI G, Perrone F, Minari R, Verze M, et al
    Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
    Clin Lung Cancer. 2022 Jul 25. pii: S1525-7304(22)00160.
    PubMed     Abstract available


  44. SHAH M, Marmarelis ME, Mamtani R, Hennessy S, et al
    Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 22. pii: S1525-7304(22)00154.
    PubMed     Abstract available


  45. GALLI G, Corsetto PA, Proto C, Lo Russo G, et al
    Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00155.
    PubMed     Abstract available


  46. TSUI DCC, Drusbosky LM, Wienke S, Gao D, et al
    Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00159.
    PubMed     Abstract available


  47. ZHOU L, Xiong Y, Wang Y, Meng Y, et al
    A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00153.
    PubMed     Abstract available


  48. ARDESHIR-LARIJANI F, Althouse SK, Leal T, Feldman LE, et al
    A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00157.
    PubMed     Abstract available


  49. AHN MJ, Kim HR, Yang JCH, Han JY, et al
    Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00152.
    PubMed     Abstract available


  50. JOSHI I, Peravali M, Geng X, Rao S, et al
    Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy.
    Clin Lung Cancer. 2022;23:438-445.
    PubMed     Abstract available


  51. BEHEL V, Chougule A, Noronha V, Patil VM, et al
    Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Clin Lung Cancer. 2022;23:410-418.
    PubMed     Abstract available


  52. SHINNO Y, Yoshida A, Masuda K, Matsumoto Y, et al
    Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Clin Lung Cancer. 2022;23:386-392.
    PubMed     Abstract available


  53. MAROONGROGE S, Weissferdt A, Buszek S, Rice DC, et al
    Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report.
    Clin Lung Cancer. 2022;23:e335-e338.
    PubMed    


    June 2022
  54. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
    Clin Lung Cancer. 2022 Jun 30. pii: S1525-7304(22)00149.
    PubMed     Abstract available


  55. OSTA BE, Carlisle J, Steuer C, Pakkala S, et al
    A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Clin Lung Cancer. 2022 Jun 22. pii: S1525-7304(22)00147.
    PubMed     Abstract available


  56. CARDONA AF, Ruiz-Patino A, Recondo G, Martin C, et al
    Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Clin Lung Cancer. 2022 Jun 6. pii: S1525-7304(22)00127.
    PubMed     Abstract available


  57. WALIANY S, Wakelee H, Ramchandran K, Das M, et al
    Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00128.
    PubMed     Abstract available


  58. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Local Control With Single-Fraction Lung Stereotactic Body Radiotherapy is not influenced by Non-Small Cell Lung Cancer Histologic Subtype.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00129.
    PubMed     Abstract available


  59. VEILLON R, Sakai H, Le X, Felip E, et al
    Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
    Clin Lung Cancer. 2022;23:320-332.
    PubMed     Abstract available


  60. COSTA BA, Maraveyas A, Wilkoff MH, Correia GSC, et al
    Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature.
    Clin Lung Cancer. 2022;23:e296-e300.
    PubMed    


  61. CAMIDGE DR, Moran T, Demedts I, Grosch H, et al
    A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
    Clin Lung Cancer. 2022;23:300-310.
    PubMed     Abstract available


  62. ANDRAOS TY, Halmos B, Cheng H, Huntzinger C, et al
    Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy.
    Clin Lung Cancer. 2022;23:291-299.
    PubMed     Abstract available


  63. GUO Y, Wei L, Patel SH, Lopez G, et al
    Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
    Clin Lung Cancer. 2022;23:345-355.
    PubMed     Abstract available


  64. FEDERICO AD, Gelsomino F, De Biase D, Ardizzoni A, et al
    Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e283-e284.
    PubMed    


    May 2022
  65. MORENO V, Roda D, Pikiel J, Trigo J, et al
    Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
    Clin Lung Cancer. 2022 May 23. pii: S1525-7304(22)00115.
    PubMed     Abstract available


  66. SIRGI Y, Krochmal R, Fleury CM, Holmes M, et al
    Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00107.
    PubMed     Abstract available


  67. CUCCHIARA F, Petrini I, Passaro A, Attili I, et al
    Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00108.
    PubMed     Abstract available


  68. NAGATA S, Hamaji M, Ozasa H, Yamada Y, et al
    Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00098.
    PubMed    


  69. ZHU F, Wang H, Ashamalla H
    The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00102.
    PubMed     Abstract available


  70. RIUDAVETS M, Lamberts V, Vasseur D, Auclin E, et al
    Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00105.
    PubMed     Abstract available


  71. LIU SM, Yan HH, Wei XW, Lu C, et al
    Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00101.
    PubMed     Abstract available


  72. BIRONZO P, Primo L, Novello S, Righi L, et al
    Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00100.
    PubMed     Abstract available


  73. FUKUSHIMA T, Oyamada Y, Ikemura S, Nukaga S, et al
    Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00099.
    PubMed     Abstract available


  74. SCHNEIDER CS, Hatic H, Das D, Cardan RA, et al
    Patterns of Failure and Optimal Treatment Paradigm for Large, Inoperable, Node-Negative Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00103.
    PubMed     Abstract available


  75. SCHMID S, Minnella EM, Pilon Y, Rokah M, et al
    Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00097.
    PubMed     Abstract available


  76. ZHOU Q, Wang M, Zhang H, Hong Q, et al
    Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study.
    Clin Lung Cancer. 2022 May 7. pii: S1525-7304(22)00037.
    PubMed     Abstract available


  77. MAYNE NR, Bajaj SS, Powell J, Elser HC, et al
    Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic.
    Clin Lung Cancer. 2022 May 5. pii: S1525-7304(22)00069.
    PubMed     Abstract available


  78. SODJI QH, Harris JP, Quon A, Modlin LA, et al
    Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
    Clin Lung Cancer. 2022;23:282-289.
    PubMed     Abstract available


  79. WHITE MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, et al
    Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    Clin Lung Cancer. 2022;23:e210-e221.
    PubMed     Abstract available


  80. FUJINO T, Suda K, Sakai K, Murakami I, et al
    Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
    Clin Lung Cancer. 2022;23:e185-e195.
    PubMed     Abstract available


  81. BELLUOMINI L, Dionisi V, Palmerio S, Vincenzi S, et al
    Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Im
    Clin Lung Cancer. 2022;23:e269-e272.
    PubMed     Abstract available


  82. REMON J, Girard N, Novello S, de Castro J, et al
    PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
    Clin Lung Cancer. 2022;23:e243-e246.
    PubMed     Abstract available


  83. YONEDA T, Sone T, Koba H, Shibata K, et al
    Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
    Clin Lung Cancer. 2022 May 1. pii: S1525-7304(22)00055.
    PubMed     Abstract available


    April 2022
  84. SCHILD SE, Wang X, Bestvina CM, Williams T, et al
    Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
    Clin Lung Cancer. 2022 Apr 30. pii: S1525-7304(22)00065.
    PubMed     Abstract available


  85. RIMNER A, Lai WV, Califano R, Jabbour SK, et al
    Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00058.
    PubMed     Abstract available


  86. ABDELGHANY K, Macaulay R, Tang Z, Tanvetyanon T, et al
    Pulmonary Ewing Sarcoma Mimicking Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00061.
    PubMed    


  87. MERKHOFER CM, Eastman B, Densmore I, Halasz LM, et al
    Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00056.
    PubMed     Abstract available


  88. ROBINSON EM, Liu BY, Sigel K, Yin C, et al
    Impact of Comorbidities on Lung Cancer Screening Evaluation.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00054.
    PubMed     Abstract available


  89. MIKAMI N, Takeda A, Hashimoto A, Takeda T, et al
    CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00064.
    PubMed     Abstract available


  90. MAJEED H, Zhu H, Williams SA, Hamann HA, et al
    Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00057.
    PubMed     Abstract available


  91. CAMIDGE DR, Mandair D, Morgan R, Amini A, et al
    Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest Imaging.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00059.
    PubMed     Abstract available


  92. JABBOUR SK, Cho BC, Bria E, Kato T, et al
    Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00066.
    PubMed     Abstract available


  93. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 27. pii: S1525-7304(21)00267.
    PubMed     Abstract available


  94. ZHANG C, Li F, Li J, Xu Y, et al
    Corrigendum to "Docetaxel downregulates PD-1 expression via STAT3 in Tlymphocytes" [Clinical Lung Cancer 19 (2018) e675-e683].
    Clin Lung Cancer. 2022 Apr 15. pii: S1525-7304(22)00040.
    PubMed    


    March 2022
  95. CIUNCI CA, Reibel JB, Evans TL, Mick R, et al
    Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Clin Lung Cancer. 2022 Mar 14. pii: S1525-7304(22)00034.
    PubMed     Abstract available


  96. HOLTZMAN L, Moskovitz M, Urban D, Nechushtan H, et al
    dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score >/=50.
    Clin Lung Cancer. 2022;23:122-134.
    PubMed     Abstract available


  97. PATHAK R, Salgia R
    Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
    Clin Lung Cancer. 2022;23:e137-e139.
    PubMed    


  98. SHAH MP, Aredo JV, Padda SK, Ramchandran KJ, et al
    EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
    Clin Lung Cancer. 2022;23:e148-e153.
    PubMed     Abstract available


  99. ASEMOTA N, Saftic I, Tsitsias T, King J, et al
    Quality of Life in Octogenarians After Lung Resection Compared to Younger Patients.
    Clin Lung Cancer. 2022;23:e118-e130.
    PubMed     Abstract available


  100. XU J, He T, Wu Y, Cao J, et al
    VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis.
    Clin Lung Cancer. 2022;23:170-176.
    PubMed     Abstract available


  101. ZHANG S, Li S, Liu J, Yang C, et al
    Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2022;23:159-169.
    PubMed     Abstract available


    February 2022
  102. PAYNE RG, Anker CJ, Sprague BL, No HJ, et al
    Active Surveillance for Early Stage Lung Cancer.
    Clin Lung Cancer. 2022 Feb 12. pii: S1525-7304(22)00012.
    PubMed     Abstract available


  103. JAZIEH AR, Saglam EK, Onal HC, Abdelkader Y, et al
    Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
    Clin Lung Cancer. 2022 Feb 11. pii: S1525-7304(22)00016.
    PubMed     Abstract available


  104. HARRIS JP, Fujimoto DK, Nagasaka M, Ku E, et al
    Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations.
    Clin Lung Cancer. 2022 Feb 10. pii: S1525-7304(22)00015.
    PubMed     Abstract available


  105. KAUFFMANN-GUERRERO D, Walter J, Kovacs J, Sellmer L, et al
    The Role of Thoracic Surgery in Small Cell Lung Cancer - A Large Longitudinal Analysis (2002-2015) Based on Real-World Data.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00009.
    PubMed     Abstract available


  106. CORTOT A, Le X, Smit E, Viteri S, et al
    Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00013.
    PubMed     Abstract available


  107. GOVINDAN R, Lind M, Insa A, Khan SA, et al
    Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00011.
    PubMed     Abstract available


  108. IZANO MA, Tran N, Fu A, Toland L, et al
    Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 3. pii: S1525-7304(22)00014.
    PubMed     Abstract available


    January 2022
  109. ALTAN M, Singhi EK, Worst M, Carter BW, et al
    Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 31. pii: S1525-7304(22)00006.
    PubMed     Abstract available


  110. MARMARELIS ME, Yang YX, Hwang WT, Mamtani R, et al
    Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00005.
    PubMed     Abstract available


  111. STOKES WA, Xiong N, Liu Y, Higgins KA, et al
    Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00007.
    PubMed     Abstract available


  112. HAYASHI H, Nadal E, Gray JE, Ardizzoni A, et al
    Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Clin Lung Cancer. 2022;23:e69-e82.
    PubMed     Abstract available


  113. LI Y, Wang K, Tian P, Li W, et al
    Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.
    Clin Lung Cancer. 2022;23:e83-e86.
    PubMed    


  114. HIRSCH FR, Walker J, Higgs BW, Cooper ZA, et al
    The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.
    Clin Lung Cancer. 2022;23:1-13.
    PubMed     Abstract available


  115. LECLAIR JN, Merl MY, Cohenuram M, Luon D, et al
    Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
    Clin Lung Cancer. 2022;23:34-42.
    PubMed     Abstract available


  116. SCHMID S, Zhan L, Dietrich K, Khan K, et al
    Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
    Clin Lung Cancer. 2022;23:e43-e53.
    PubMed     Abstract available


  117. CAREY ET, Ferreira V, Shum E, Zhou F, et al
    The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e1-e4.
    PubMed     Abstract available


    December 2021
  118. ZHANG L, Yang X, Ming Z, Shi J, et al
    Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00304.
    PubMed     Abstract available


  119. HIJMERING-KAPPELLE LBM, Hiltermann TJN, Bensch F
    Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00305.
    PubMed     Abstract available


  120. LOGTENBERG ME, Tomlow B, Kastelijn EA, Schramel FMNH, et al
    Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 17. pii: S1525-7304(21)00291.
    PubMed     Abstract available


  121. AKHTAR A, Sosa E, Castro S, Sur M, et al
    A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers.
    Clin Lung Cancer. 2021 Dec 12. pii: S1525-7304(21)00289.
    PubMed     Abstract available


  122. YAGA M, Shiroyama T, Hirata H, Oya K, et al
    Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00290.
    PubMed    


  123. KEE W, Ng KYY, Lee JJX, Tan DSW, et al
    Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00288.
    PubMed    


    November 2021
  124. GANESH A, Katipally R, Pasquinelli M, Feldman L, et al
    Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States.
    Clin Lung Cancer. 2021 Nov 25. pii: S1525-7304(21)00287.
    PubMed     Abstract available


  125. HEYNEMANN S, Yu H, Churilov L, Rivalland G, et al
    NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
    Clin Lung Cancer. 2021 Nov 16. pii: S1525-7304(21)00281.
    PubMed     Abstract available


  126. ALDIN MK, Qi L, Zhou X, Kahn LA, et al
    Detection of second primary lung cancers on surveillance imaging following stereotactic ablative radiotherapy for non-small cell lung cancer.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00280.
    PubMed     Abstract available


  127. CATANIA C, Muthusamy B, Spitaleri G, Del Signore E, et al
    The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00279.
    PubMed     Abstract available


  128. HOCHMAIR MJ, Illini O, Prosch H, Krenbek D, et al
    Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.
    Clin Lung Cancer. 2021 Nov 10. pii: S1525-7304(21)00277.
    PubMed    


  129. SUVEG K, Le Pechoux C, Faivre-Finn C, Putora PM, et al
    Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.
    Clin Lung Cancer. 2021;22:579-586.
    PubMed     Abstract available


  130. WATERHOUSE DM, Tseng WY, Espirito JL, Robert NJ, et al
    Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.
    Clin Lung Cancer. 2021;22:e901-e910.
    PubMed     Abstract available


  131. WANG B, Hamal P, Sun K, Bhuva MS, et al
    Clinical Value and Pathologic Basis of Cystic Airspace Within Subsolid Nodules Confirmed as Lung Adenocarcinomas by Surgery.
    Clin Lung Cancer. 2021;22:e881-e888.
    PubMed     Abstract available


  132. WANG CY, Hsia JY, Li CH, Ho CC, et al
    Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
    Clin Lung Cancer. 2021;22:e878-e880.
    PubMed    


  133. CLEMENT MS, Ebert EBF, Meldgaard P, Sorensen BS, et al
    Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
    Clin Lung Cancer. 2021;22:e870-e877.
    PubMed     Abstract available


  134. YU J, Du Y, Mekhail T, Socinski MA, et al
    Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy.
    Clin Lung Cancer. 2021;22:e856-e858.
    PubMed    


  135. JI J, Mitra A, Camidge DR, Riess JW, et al
    Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
    Clin Lung Cancer. 2021;22:e851-e855.
    PubMed    


  136. FURUTA H, Kato S, Masago K, Hida T, et al
    Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:e829-e832.
    PubMed    


  137. SHIGENOBU T, Takahashi Y, Masugi Y, Hanawa R, et al
    Micropapillary Predominance Is a Risk Factor for Brain Metastasis in Resected Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e820-e828.
    PubMed     Abstract available


  138. CECCHI C, Mariniello A, Carnio S, Delcuratolo MD, et al
    Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature.
    Clin Lung Cancer. 2021;22:e804-e807.
    PubMed    


    October 2021
  139. XIAOBING L, Meipan Y, Pengfei X, Yue Z, et al
    Bronchial Artery Chemoembolization for Hemoptysis in Advanced Primary Lung Cancer.
    Clin Lung Cancer. 2021 Oct 29. pii: S1525-7304(21)00272.
    PubMed     Abstract available


  140. SHIRAISHI Y, Hakozaki T, Nomura S, Kataoka T, et al
    A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene A
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00271.
    PubMed     Abstract available


  141. GARON EB, Peterson P, Rizzo MT, Kim JS, et al
    Overall Survival and Safety With Pemetrexed/Platinum +/- Anti-VEGF Followed by Pemetrexed +/- Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00274.
    PubMed     Abstract available


  142. SONODA D, Matsuura Y, Kondo Y, Ichinose J, et al
    A Reasonable Definition of Oligo-Recurrence in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00276.
    PubMed     Abstract available


  143. DOYEN J, Besse B, Texier M, Bonnet N, et al
    PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial.
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00269.
    PubMed     Abstract available


  144. HARATAKE N, Hayashi H, Shimokawa M, Nakano Y, et al
    Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00270.
    PubMed     Abstract available


  145. LI J, Wang Y, Li J, Cao S, et al
    Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces.
    Clin Lung Cancer. 2021 Oct 23. pii: S1525-7304(21)00268.
    PubMed     Abstract available


  146. HELLYER JA, White MN, Gardner RM, Cunanan K, et al
    Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
    Clin Lung Cancer. 2021 Oct 21. pii: S1525-7304(21)00245.
    PubMed     Abstract available


  147. NAGASAKA M, Singh V, Baca Y, Sukari A, et al
    The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 18. pii: S1525-7304(21)00244.
    PubMed     Abstract available


  148. HIRSCH FR, Redman MW, Moon J, Agustoni F, et al
    EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCL
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00263.
    PubMed     Abstract available


  149. SUDA K, Ohara S, Fujino T, Hamada A, et al
    Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00264.
    PubMed     Abstract available


  150. PAGE RD, Drusbosky LM, Dada H, Raymond VM, et al
    Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00262.
    PubMed     Abstract available


  151. LELEU O, Basille D, Auquier M, Clarot C, et al
    Results of Second Round Lung Cancer Screening by Low-Dose CT scan - French Cohort Study (DEP-KP80).
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00261.
    PubMed     Abstract available


  152. HEYMACH JV, Mitsudomi T, Harpole D, Aperghis M, et al
    Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00265.
    PubMed     Abstract available


  153. YAMASAKI N, Kim YH, Iwatsubo S, Nishimura Y, et al
    Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 2. pii: S1525-7304(21)00249.
    PubMed    


    September 2021
  154. KUEHNE N, Hueniken K, Xu M, Shakik S, et al
    Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data.
    Clin Lung Cancer. 2021 Sep 25. pii: S1525-7304(21)00247.
    PubMed     Abstract available


  155. NAKAO M, Saji H, Mun M, Nakamura H, et al
    Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303.
    Clin Lung Cancer. 2021 Sep 24. pii: S1525-7304(21)00248.
    PubMed     Abstract available


  156. TU HY, Li YS, Bai XY, Sun YL, et al
    Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Clin Lung Cancer. 2021 Sep 20. pii: S1525-7304(21)00242.
    PubMed     Abstract available


  157. SAKAGUCHI T, Kokubo Y, Furuhashi K, Nakamura Y, et al
    An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00241.
    PubMed    


  158. HAO Z, Sekkath Veedu J
    Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00243.
    PubMed     Abstract available


  159. LI X, Sun J, Wang L
    NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.
    Clin Lung Cancer. 2021;22:480-481.
    PubMed    


  160. ALTAN M, Patel AB
    Management of Cutaneous Immunotherapy Toxicities.
    Clin Lung Cancer. 2021;22:e783.
    PubMed    


  161. HUANG WL, Liu YW
    The Role of Stereotactic Body Radiation Therapy for Pulmonary Carcinosarcoma.
    Clin Lung Cancer. 2021;22:e684-e685.
    PubMed    


  162. NASSER A, Baird A, Saint-Pierre MD, Amjadi K, et al
    Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience.
    Clin Lung Cancer. 2021;22:441-448.
    PubMed     Abstract available


  163. VEKENS K, Everaert H, Neyns B, Ilsen B, et al
    The Value of (18)F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Clin Lung Cancer. 2021;22:432-440.
    PubMed     Abstract available


  164. LIM JU
    Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021;22:e786-e792.
    PubMed     Abstract available


  165. TAKAO T, Tanaka K, Shiraishi Y, Ota K, et al
    Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.
    Clin Lung Cancer. 2021;22:e784-e785.
    PubMed    


  166. GILES AE, Teferi Y, Kidane B, Bayaraa B, et al
    Lung Resection Without Tissue Diagnosis: A Pragmatic Perspective on the Indeterminate Pulmonary Nodule.
    Clin Lung Cancer. 2021;22:e774-e781.
    PubMed     Abstract available


  167. PERNA M, Scotti V, Ciammella P, Borghetti P, et al
    The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC.
    Clin Lung Cancer. 2021;22:e767-e773.
    PubMed     Abstract available


  168. LEONETTI A, Minari R, Boni L, Gnetti L, et al
    Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Clin Lung Cancer. 2021;22:473-477.
    PubMed     Abstract available


  169. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e712-e715.
    PubMed    


  170. HARADA G, Amano MT, Antonacio FF, Behar MH, et al
    Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e708-e711.
    PubMed     Abstract available


  171. FROST N, Kollmeier J, Misch D, Vollbrecht C, et al
    Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (>/= 50%) NSCLC: Real-world Results with Special Focus on PS >/= 2, Brain Metastases, and Steroids.
    Clin Lung Cancer. 2021;22:411-422.
    PubMed     Abstract available


  172. ZHANG Y, Wang H, Wang X, Li S, et al
    Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report.
    Clin Lung Cancer. 2021;22:e699-e702.
    PubMed    


  173. WADDINGTON T, Mambetsariev I, Pharaon R, Fricke J, et al
    Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
    Clin Lung Cancer. 2021;22:e703-e707.
    PubMed    


  174. DOUBRE H, Fraboulet S, Longchampt E, Damotte D, et al
    ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors.
    Clin Lung Cancer. 2021;22:e686-e690.
    PubMed    


  175. AREDO JV, Diehn M, Berry GJ, Wakelee HA, et al
    Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.
    Clin Lung Cancer. 2021;22:e673-e677.
    PubMed    


  176. DAVIS A, Mahar A, Wong K, Barnet M, et al
    Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Clin Lung Cancer. 2021;22:e665-e667.
    PubMed    


    August 2021
  177. MYNARD N, Saxena A, Mavracick A, Port J, et al
    Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report.
    Clin Lung Cancer. 2021 Aug 29. pii: S1525-7304(21)00214.
    PubMed     Abstract available


  178. JIN Y, Xue Q, Shen X, Zheng Q, et al
    PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.
    Clin Lung Cancer. 2021 Aug 28. pii: S1525-7304(21)00213.
    PubMed     Abstract available


  179. SEITLINGER J, Prieto M, Guerrera F, Streit A, et al
    Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes.
    Clin Lung Cancer. 2021 Aug 22. pii: S1525-7304(21)00205.
    PubMed     Abstract available


  180. WOODARD GA, Kratz JR, Haro G, Gubens MA, et al
    Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Clin Lung Cancer. 2021 Aug 20. pii: S1525-7304(21)00212.
    PubMed     Abstract available


  181. TAKADA K, Takamori S, Miura N, Shikada Y, et al
    Comments on 'The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors'.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00208.
    PubMed    


  182. LEE M, Patel D, Jofre S, Fidvi S, et al
    Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00206.
    PubMed    


    July 2021
  183. LI X, Chen X, He S, Chen H, et al
    The Application of Pigtail Catheters in Postoperative Drainage of Lung Cancer.
    Clin Lung Cancer. 2021 Jul 31. pii: S1525-7304(21)00191.
    PubMed     Abstract available


  184. REUSS JE, Gosa L, Liu SV
    Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Clin Lung Cancer. 2021 Jul 25. pii: S1525-7304(21)00192.
    PubMed     Abstract available


  185. GJYSHI O, Lin SH, Pezzi TA, Ning MS, et al
    Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2021 Jul 24. pii: S1525-7304(21)00184.
    PubMed     Abstract available


  186. UMEMURA S, Chen V, Chahine JJ, Kallakury B, et al
    Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00187.
    PubMed     Abstract available


  187. WONG DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, et al
    Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00183.
    PubMed     Abstract available


  188. SINGH S, Pavesi F, Steiling K, Asokan S, et al
    Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort.
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00190.
    PubMed     Abstract available


  189. DE RUYSSCHER D, Ramalingam S, Urbanic J, Gerber DE, et al
    CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-S
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00186.
    PubMed     Abstract available


  190. TAKAMORI S, Takada K, Shimokawa M, Okamoto T, et al
    Comments on "Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study".
    Clin Lung Cancer. 2021 Jul 7. pii: S1525-7304(21)00181.
    PubMed    


  191. MANGLAVITI S, Brambilla M, Signorelli D, Ferrara R, et al
    Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
    Clin Lung Cancer. 2021 Jul 5. pii: S1525-7304(21)00180.
    PubMed     Abstract available


  192. KOOPMAN B, Groen HJM, Schuuring E, Hiltermann TJN, et al
    Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00178.
    PubMed     Abstract available


  193. TSUI DCC, Aisner D, Nijmeh H, Bao L, et al
    Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00179.
    PubMed    


  194. YIN J, Xi J, Liang J, Zhan C, et al
    Solid Components in the Mediastinal Window of Computed Tomography Define a Distinct Subtype of Subsolid Nodules in Clinical Stage I Lung Cancers.
    Clin Lung Cancer. 2021;22:324-331.
    PubMed     Abstract available


  195. KIM ES, Kish JK, Cseh A, Moehring B, et al
    Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
    Clin Lung Cancer. 2021;22:292-300.
    PubMed     Abstract available


  196. SHIRASAWA M, Yoshida T, Takayanagi D, Shiraishi K, et al
    Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:282-291.
    PubMed     Abstract available


  197. TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
    A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-
    Clin Lung Cancer. 2021;22:376-380.
    PubMed     Abstract available


  198. RAMALINGAM S, Dinan MA, Crawford J
    Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.
    Clin Lung Cancer. 2021;22:e646-e653.
    PubMed     Abstract available


  199. LAU SCM, Fares AF, Le LW, Mackay KM, et al
    Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:253-259.
    PubMed     Abstract available


  200. NAAMAN R, Lautenschlaeger T, Diab K
    Feasibility of Performing Transvascular Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.
    Clin Lung Cancer. 2021;22:e595-e601.
    PubMed     Abstract available


  201. TAYLOR M, Grant SW, West D, Shackcloth M, et al
    Ninety-Day Mortality: Redefining the Perioperative Period After Lung Resection.
    Clin Lung Cancer. 2021;22:e642-e645.
    PubMed     Abstract available


  202. REGNERY S, Eichkorn T, Weykamp F, Held T, et al
    Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
    Clin Lung Cancer. 2021;22:332-340.
    PubMed     Abstract available


  203. RALKI M, Serrien A, Lambert J, Leys M, et al
    Brown-Sequard Syndrome in a Desmoplastic Malignant Mesothelioma Patient: A Rare Complication.
    Clin Lung Cancer. 2021;22:e552-e554.
    PubMed    


  204. LEE PH, Chang GC
    Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e536-e541.
    PubMed    


  205. TAO L, Miao R, Mekhail T, Sun J, et al
    Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e506-e511.
    PubMed     Abstract available


  206. KERKHOFF JW, Vreuls W, Vermeer LC
    Mesothelioma Micronodular Metastasis Pattern Confirmed by Transbronchial Cryobiopsy: Case Report.
    Clin Lung Cancer. 2021;22:e533-e535.
    PubMed    


  207. CORTINOVIS D, Grosso F, Carlucci L, Zucali PA, et al
    Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
    Clin Lung Cancer. 2021;22:361-370.
    PubMed     Abstract available


  208. SASSOROSSI C, Lococo F, Pogliani L, Tabacco D, et al
    Factors Affecting Long-Term Survival in Locally Advanced NSCLC Patients With Pathologic Complete Response After Induction Therapy Followed by Surgical Resection.
    Clin Lung Cancer. 2021;22:e542-e543.
    PubMed    


    June 2021
  209. YU HA, Goldberg SB, Le X, Piotrowska Z, et al
    Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Clin Lung Cancer. 2021 Jun 25. pii: S1525-7304(21)00157.
    PubMed     Abstract available


  210. YANG Y, Deng L, Yang Y, Zhang T, et al
    Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00160.
    PubMed     Abstract available


  211. JACOBS CD, Mehta K, Gao J, Wang X, et al
    Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00159.
    PubMed     Abstract available


  212. BARTA JA, Shusted CS, Ruane B, Pimpinelli M, et al
    Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00143.
    PubMed     Abstract available


  213. SAITO G, Kono M, Koyanagi Y, Miyashita K, et al
    Significance of Brain Imaging for Staging in Patients With Clinical Stage T1-2 N0 Non-Small-Cell Lung Cancer on Positron Emission Tomography/Computed Tomography.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00145.
    PubMed     Abstract available


  214. PINQUIE F, Cortot AB, Chevalier LM, Morel A, et al
    A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00142.
    PubMed    


  215. TSUI DCC, Kavanagh BD, Honce JM, Rossi C, et al
    Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00148.
    PubMed    


  216. HENDRIKS LEL, Remon J, Besse B
    Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00149.
    PubMed    


  217. SOCINSKI MA, Ozguroglu M, Villegas A, Daniel D, et al
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00144.
    PubMed     Abstract available


    May 2021
  218. GADGEEL S, Hirsch FR, Kerr K, Barlesi F, et al
    Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Clin Lung Cancer. 2021 May 30. pii: S1525-7304(21)00101.
    PubMed     Abstract available


  219. LI Y, Zhang Y, Jia X, Jiang P, et al
    Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2021 May 28. pii: S1525-7304(21)00098.
    PubMed     Abstract available


  220. LEAL JL, Alexander M, Itchins M, Wright GM, et al
    EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 May 16. pii: S1525-7304(21)00093.
    PubMed     Abstract available


  221. RIESS JW, Reckamp KL, Frankel P, Longmate J, et al
    Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Clin Lung Cancer. 2021 May 15. pii: S1525-7304(21)00094.
    PubMed     Abstract available


  222. RIESS JW, Rolfo C, Gandara DR
    Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.
    Clin Lung Cancer. 2021;22:153-155.
    PubMed    


  223. PRINZI N, Rossi RE, Proto C, Leuzzi G, et al
    Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Clin Lung Cancer. 2021;22:161-169.
    PubMed     Abstract available


  224. WHITE MN, Piotrowska Z, Stirling K, Liu SV, et al
    Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    Clin Lung Cancer. 2021;22:201-209.
    PubMed     Abstract available


  225. SAMUEL E, Lie G, Balasubramanian A, Hiong A, et al
    Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e425-e430.
    PubMed     Abstract available


  226. GADOTTI LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, et al
    Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e481-e486.
    PubMed    


  227. ZENG YW, Liu Y, Qi Y, Yin MP, et al
    Bronchial Arterial Infusion Chemotherapy Plus Drug-eluting Bead Chemoembolization for Recurrence of Carina Region-induced Severe Right Main Bronchial Stenosis After Pneumonectomy.
    Clin Lung Cancer. 2021;22:e293-e297.
    PubMed    


  228. BEHRENS C, Rocha P, Parra ER, Feng L, et al
    Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e415-e424.
    PubMed     Abstract available


  229. PENG LP
    Regarding: MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
    Clin Lung Cancer. 2021;22:e446-e450.
    PubMed    


  230. CHAPMAN BV, Ning MS, Farnia B, Mesko S, et al
    Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields.
    Clin Lung Cancer. 2021;22:225-233.
    PubMed     Abstract available


  231. PATEL A, Roshkovan L, McNulty S, Alley E, et al
    Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
    Clin Lung Cancer. 2021;22:210-217.
    PubMed     Abstract available


  232. XIE Z, Gu Y, Xie X, Lin X, et al
    Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
    Clin Lung Cancer. 2021;22:e390-e394.
    PubMed    


  233. KOZLOV A, Pantel A, Iagaru A, Ikeda D, et al
    Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging (18)F-FDG PET/CT in a Woman With a Normal Screening Mammogram.
    Clin Lung Cancer. 2021;22:e438-e441.
    PubMed    


  234. COUDERC AL, Tomasini P, Nouguerede E, Rey D, et al
    Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.
    Clin Lung Cancer. 2021;22:e405-e414.
    PubMed     Abstract available


  235. TSUTANI Y, Nakayama H, Ito H, Handa Y, et al
    Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [(18)F]-Fluoro-2-Deoxy-d-Glucose Positron Emissio
    Clin Lung Cancer. 2021;22:e431-e437.
    PubMed     Abstract available


  236. KANDER EM, Shah MH, Zhou Y, Goyal A, et al
    Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
    Clin Lung Cancer. 2021;22:e442-e445.
    PubMed    


  237. KUNTE S, Stevenson J
    A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e298-e300.
    PubMed    


  238. WANG S, Wu X, Zhao J, Chen H, et al
    Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:e366-e370.
    PubMed    


  239. TAMIYA A, Isa SI, Taniguchi Y, Nakagawa H, et al
    Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Clin Lung Cancer. 2021;22:e336-e341.
    PubMed     Abstract available


  240. ZHOU M, Joshi N, Raj KP, Wakelee H, et al
    PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
    Clin Lung Cancer. 2021;22:e329-e335.
    PubMed    


    April 2021
  241. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00090.
    PubMed     Abstract available


  242. OYANAGI J, Koh Y, Sato K, Teraoka S, et al
    Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00091.
    PubMed     Abstract available


  243. BYERS LA, Navarro A, Schaefer E, Johnson M, et al
    A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 24. pii: S1525-7304(21)00089.
    PubMed     Abstract available


  244. FISHER A, Kim S, Farhat D, Belzer K, et al
    Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.
    Clin Lung Cancer. 2021 Apr 23. pii: S1525-7304(21)00088.
    PubMed     Abstract available


  245. MERKHOFER CM, Eaton KD, Martins RG, Ramsey SD, et al
    Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 22. pii: S1525-7304(21)00087.
    PubMed     Abstract available


  246. RAEZ LE, Carracedo C, Drusbosky LM, Velez M, et al
    EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.
    Clin Lung Cancer. 2021 Apr 9. pii: S1525-7304(21)00072.
    PubMed    


    March 2021
  247. MORAN A, Wang Y, Dyer BA, Yip SSF, et al
    Prognostic Value of Computed Tomography and/or (18)F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00069.
    PubMed     Abstract available


  248. ARRIETA O, Varela-Santoyo E, Cardona AF, Sanchez-Reyes R, et al
    Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00068.
    PubMed     Abstract available


  249. KAO C, Powers E, Wu Y, Datto MB, et al
    Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00071.
    PubMed     Abstract available


  250. SHEN Q, Kalyani FS, Qu J, Chen Z, et al
    A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00066.
    PubMed    


  251. WEISS J, Goldschmidt J, Andric Z, Dragnev KH, et al
    Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00064.
    PubMed     Abstract available


  252. BRAINSON CF, Huang B, Chen Q, McLouth LE, et al
    Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00061.
    PubMed     Abstract available


  253. KELLER A, Ghanta S, Rodriguez-Lopez JL, Patel A, et al
    Utility of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer in the MRI Screening Era.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00063.
    PubMed     Abstract available


  254. CABEZON-GUTIERREZ L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, et al
    Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Clin Lung Cancer. 2021 Mar 24. pii: S1525-7304(21)00060.
    PubMed     Abstract available


  255. DALL'OLIO FG, Gelsomino F, Conci N, Marcolin L, et al
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 16. pii: S1525-7304(21)00057.
    PubMed     Abstract available


  256. UPRETY D
    CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2021;22:71-73.
    PubMed    


  257. TAKEYASU Y, Yoshida T, Shibaki R, Matsumoto Y, et al
    Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS >/= 50%) NSCLC.
    Clin Lung Cancer. 2021;22:127-133.
    PubMed     Abstract available


  258. MOUNTZIOS G, de Toma A, Economopoulou P, Friedlaender A, et al
    Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
    Clin Lung Cancer. 2021;22:e180-e192.
    PubMed     Abstract available


  259. ZHANG C, He Z, Cheng J, Cao J, et al
    Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Clin Lung Cancer. 2021;22:e160-e168.
    PubMed     Abstract available


  260. SHAH R, Klotz LV, Chung I, Feisst M, et al
    A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Clin Lung Cancer. 2021;22:142-146.
    PubMed     Abstract available


  261. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e157-e159.
    PubMed    


  262. SUDA K, Sakai K, Obata K, Ohara S, et al
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
    Clin Lung Cancer. 2021;22:e141-e145.
    PubMed     Abstract available


    February 2021
  263. KOGURE Y, Hashimoto H, Oki M
    A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00031.
    PubMed     Abstract available


    January 2021
  264. RIESS JW, Frankel P, Shackelford D, Dunphy M, et al
    Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
    Clin Lung Cancer. 2021;22:67-70.
    PubMed     Abstract available


  265. URBAN L, Doczi R, Vodicska B, Tihanyi D, et al
    Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Clin Lung Cancer. 2021;22:e112-e115.
    PubMed    


  266. STEBER CR, Hughes RT, Soike MH, Jacobson T, et al
    Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e122-e131.
    PubMed     Abstract available


  267. NAGASAKA M, Fisher A, Chowdhury T, Ge Y, et al
    PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Clin Lung Cancer. 2021;22:e51-e53.
    PubMed    


  268. EMEREL L, Trejo Bittar H, Okusanya OT
    A Rare Presentation of Primary Pulmonary Synovial Sarcoma.
    Clin Lung Cancer. 2021;22:e48-e50.
    PubMed    


  269. CHEN K, Zhang F, Pan G, Sheng J, et al
    A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e1-e4.
    PubMed    


    March 2020
  270. GELSOMINO F, Di Federico A, Filippini DM, Dall'Olio FG, et al
    Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Clin Lung Cancer. 2020;21:e45-e48.
    PubMed    


  271. BARBOSA MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, et al
    High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Clin Lung Cancer. 2020;21:e37-e44.
    PubMed    


  272. MATSUBARA T, Uchi H, Haratake N, Takamori S, et al
    Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Clin Lung Cancer. 2020;21:e54-e56.
    PubMed    


  273. MAZZASCHI G, Bordi P, Fioretzaki R, Gnetti L, et al
    Nivolumab-Induced Guillain-Barre Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e65-e73.
    PubMed    


  274. TANNER NT, Brasher PB, Jett J, Silvestri GA, et al
    Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
    Clin Lung Cancer. 2020;21:e89-e98.
    PubMed     Abstract available


  275. ZHANG Y, Yu M, Yuan M, Chen R, et al
    Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Clin Lung Cancer. 2020;21:e78-e83.
    PubMed    


  276. KINSLOW CJ, May MS, Saqi A, Shu CA, et al
    Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Clin Lung Cancer. 2020;21:e99-e113.
    PubMed     Abstract available


  277. ERSEK JL, Symanowski JT, Han Y, Howard A, et al
    Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Clin Lung Cancer. 2020;21:160-170.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: